

Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the **February 1, 2020** Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at www.ab.bluecross.ca/dbl/publications.php

Please refer to the February 1, 2020 updates for complete listings of products available by special authorization, products available by step therapy/special authorization, products available by restricted benefit/special authorization, products with changes to criteria for coverage, restricted benefits, added products, new established interchangeable groupings, LCA price changes, products with a price change, and discontinued listings.

Please note that the online *Interactive Drug Benefit List (iDBL)* at www.ab.bluecross.ca/dbl/idbl_main1.php is a near real-time application, and as such, contains the most up-to-date information.

Product supply shortage addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Sandoz Canada Inc. that the shortage for Sandoz Voriconazole 200 mg Tablet (DIN 02399253) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **February 20, 2020**.

VORICONAZOLE

200 MG TABLET

00002399253	SANDOZ VORICONAZOLE	SDZ	\$ 26.4807
00002396874	TEVA-VORICONAZOLE	TEV	\$ 26.4807
00002256479	VFEND	PFI	\$ 53.3843

... continued from previous page

Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Adalat XL 30 mg Extended-Release Tablet (DIN 02155907) manufactured by Bayer Inc. and Mylan-Nifedipine 30 mg Extended-Release Tablet (DIN 02349167) manufactured by Mylan Pharmaceuticals ULC, pms-Nifedipine ER 30 mg Extended-Release Tablet (DIN 02418630) manufactured by Pharmascience Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Bayer Inc. has advised Alberta Blue Cross that the shortage of Adalat XL 30 mg Extended-Release Tablet (DIN 02155907) has been resolved.

As a result, pms-Nifedipine ER 30 mg Extended-Release Tablet (DIN 02418630) will no longer be considered a temporary benefit for the *ADBL* after **February 25, 2020**.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)

FAX 780-498-8406 (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit ab.bluecross.ca/providers/pharmacy-home.php**



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.838 2020/01

